Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
measles-mumps-rubella-varicella vaccine
- Development stage
- Approved
- Lead developer
- Merck
- Modality
- Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
The measles-mumps-rubella-varicella (MMRV) vaccine is a combination live attenuated viral vaccine that provides immunization against four diseases: measles, mumps, rubella (German measles), and varicella (chickenpox). It is administered as a single injection to children typically between 12 months and 12 years of age. The mechanism of action involves stimulating the immune system to produce antibodies against each virus without causing disease. This confers long-lasting immunity in most recipients. The primary indication for the MMRV vaccine is the prevention of these four infectious diseases in pediatric populations. Major brands include ProQuad (Merck) and Priorix Tetra (GSK)[8][1][3].
- Brand names
- ProQuadPriorix Tetra
- Other names
- Measles, Mumps, Rubella, and Varicella Virus Vaccine LiveMMRV vaccine
02
Targets
VZV (Varicella-zoster virus)
Beyond the preview
Go deeper on measles-mumps-rubella-varicella vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on measles-mumps-rubella-varicella vaccine.